Gilead Sciences

$59.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.53 (+0.89%) Today
-$0.04 (-0.07%) As of 6:22 AM EST after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, and ETFs commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA. The listed name for GILD is Gilead Sciences, Inc. Common Stock.

CEO
Daniel P. O'Day
Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
75.25B
Price-Earnings Ratio
62.27
Dividend Yield
4.45
Average Volume
8.42M
High Today
$60.05
Low Today
$59.28
Open Price
$59.67
Volume
5.03M
52 Week High
$85.97
52 Week Low
$57.04

Collections

GILD Earnings

$0.00
$0.70
$1.41
$2.11
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 2, After Hours

You May Also Like